Daxor jumps after study published in Annals of Thoracic Surgery

Small-cap medical device firm Daxor (DXR) is up around 10% after announcing earlier a study published in The Annals of Thoracic Surgery. The paper, entitled "Measurement of Blood Loss in Cardiac Surgery: Still Too Much," appears in the April issue. Study author Mark Nelson, MD of Virginia Commonwealth University, stated that the surprising results of his study showed the inadequacy of current methods of evaluating blood loss, including the widespread use of hematocrit and hemoglobin: "Contrary to the long-held belief that red blood cells are largely conserved during cardiac surgery they are in fact reduced by 38%." He added, "This data beckons the question of transfusion, should peripheral hematocrit continue to be utilized as a determinant." CEO COMMENTS ON BVA-100: Michael Feldschuh CEO of Daxor stated, "This study highlights the BVA-100's unique ability to illuminate intravascular fluid derangements that are missed by standard diagnostic tests. With over 500,000 coronary bypass surgeries, 3,200 transplants, and hundreds of thousands of other cardiac and non-cardiac surgeries performed annually in the United State, the need for optimal care and accurate measurement of surgical blood loss is acute."Surgical and non-surgical anemia caused by blood loss is a common ailment that poses significant risk to patients. Standard tests for determining blood loss or anemia lack the specificity and sensitivity of the BVA-100 test, which precisely quantifies whole blood and red blood cell volume with 98% accuracy. PRICE ACTION: Shares of Daxor are up 9.77% to $8.54 per share in afternoon trading.